Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy

Stopped early · Phase 1/Phase 2

Conditions studied: Prostate Cancer

In brief

In standard prostate brachytherapy treatment, the seeds are placed throughout the prostate to treat the entire gland. This is done because, in the past, it was impossible to know where the cancer was located within the prostate. Multiparametric magnetic resonance imaging (MRI) can identify tumor(s) with a high degree of accuracy. This trial will assess whether using MRI to guide prostate brachytherapy can result in less chronic toxicity by allowing lower doses to be delivered to the regions of the prostate without tumor while simultaneously allowing higher doses to the tumor. Subjects enrolled in this study will then be followed over two years and evaluated for toxicity. In addition, after two years they will undergo an MRI and a biopsy to assess the cancer control rate of the treatment.

Key facts

Study ID

NCT01913197

Run by

St. Luke's-Roosevelt Hospital Center

People needed

2

Starts

2013-08-01

Expected to finish

2016-11-01

Last updated by the study team

2017-01-06

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Clinical stage ≤ T2b according to the American Joint Commission on Cancer 6th Edition28
• PSA ≤ 15 ng/ml
• Gleason sum on biopsy ≤ 6 or 3+4=7
• Prostate volume ≤ 60 cc
• Willing to continue follow-up for at least two years

You may not qualify if…

• Prior hormone therapy
• Prior radiotherapy
• History of collagen vascular disease
• History of inflammatory bowel disease

Where it is running

• Saint Lukes-Roosevelt Hospital Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.